
|Articles|June 1, 2003
Formulation makes a difference
When prescribing ophthalmic drugs, the decision of whether to opt for a generic substitute involves greater consideration than may be required for a systemic agent.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
2
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


